1. Renal cell carcinoma (RCC), the most common type of kidney cancer, originates from the proximal tubular epithelium and accounts for approximately 90% of malignant renal tumors. Its incidence has been steadily increasing, partly due to widespread imaging use detecting incidental lesions. RCC demonstrates diverse histological subtypes with distinct molecular profiles and clinical behaviors. Clear cell RCC represents 70-80% of cases and is characterized by VHL gene mutations leading to HIF pathway activation. Papillary RCC (10-15%) includes type 1 (MET mutations) and more aggressive type 2 variants. Chromophobe RCC (5%) typically carries better prognosis, while rare subtypes like collecting duct and medullary carcinomas exhibit particularly aggressive courses.

2. Benign renal tumors represent a diverse group of non-malignant kidney lesions that are increasingly detected incidentally due to widespread use of cross-sectional imaging. These tumors account for approximately 20% of resected renal masses and require accurate differentiation from renal cell carcinoma to avoid unnecessary aggressive treatment. The most common benign renal tumors include renal oncocytomas, angiomyolipomas (AMLs), and renal cysts with benign features, each with distinct pathological and radiological characteristics. Renal oncocytomas are well-circumscribed epithelial tumors originating from the collecting ducts, typically appearing as homogeneous, solid masses with a central scar on imaging. Angiomyolipomas, composed of varying proportions of blood vessels, smooth muscle, and fat, are the most prevalent benign renal tumors and demonstrate pathognomonic fat components on CT imaging. Other less common benign entities include metanephric adenoma, a rare epithelial tumor with excellent prognosis, and renal leiomyoma, arising from smooth muscle cells in the renal capsule or pelvis.

3. Adrenal tumors encompass a diverse spectrum of benign and malignant growths arising from the adrenal cortex or medulla, with clinical significance ranging from incidental asymptomatic findings to life-threatening endocrine disorders. These tumors are increasingly detected incidentally as adrenal incidentalomas during abdominal imaging, occurring in approximately 4% of CT scans, with the prevalence increasing with age. Functionally, adrenal tumors are classified as hormonally active or non-functioning, with the former including pheochromocytomas (catecholamine-secreting), aldosterone-producing adenomas (causing Conn's syndrome), and cortisol-secreting adenomas (resulting in Cushing's syndrome). Non-functioning adenomas represent the majority of adrenal incidentalomas, while malignant etiologies such as adrenocortical carcinoma and metastatic lesions account for about 5-10% of cases. The diagnostic workup involves detailed endocrine evaluation including 24-hour urine metanephrines, aldosterone-renin ratio, and dexamethasone suppression tests, combined with dedicated adrenal protocol CT or MRI to assess imaging characteristics such as lipid content, washout patterns, and size.

4. Ureteral tumors are rare neoplasms that arise from the epithelial lining of the ureter, with the majority (90%) being malignant and primarily consisting of urothelial carcinoma (transitional cell carcinoma). These tumors account for only 5% of all upper urinary tract urothelial malignancies, with a higher incidence in males and typically presenting in the sixth to seventh decade of life. Known risk factors include smoking, occupational exposure to aromatic amines, chronic analgesic abuse, and hereditary factors such as Lynch syndrome. Clinically, patients often present with hematuria (70-80% of cases), flank pain (20-30%), or less commonly with urinary tract obstruction and associated hydronephrosis. 

5. Renal pelvic cancer, predominantly urothelial carcinoma (90-95% of cases), represents a malignancy arising from the epithelial lining of the renal pelvis, accounting for approximately 5-10% of all upper urinary tract tumors and 5% of all renal malignancies. This disease shares similar risk factors with bladder cancer, including tobacco smoking (primary risk factor), occupational exposure to aromatic amines, chronic phenacetin use, Balkan nephropathy, and hereditary factors such as Lynch syndrome. Clinically, patients typically present with gross or microscopic hematuria (70-80%), flank pain (20-30%), or less commonly with urinary obstruction symptoms.